^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Pozenveo (poziotinib) (HER2 inhibitor, HER4 inhibitor, pan-EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

    Excerpt:
    ...NSCLC with documented EGFR exon 20 mutation by one of the following Clinical Laboratory Improvement Act (CLIA) certified tests: OncoMine Comprehensive Assay (OCA), Guardant360 Assay (using plasma), or FoundationOne Assay or by a Food and Drug Administration (FDA) approved device using cobas EGFR mutation test version (v)2 or therascreen EGFR RGQ PCt kit; Mutations include D770_N771insSVD, D770_N771insNPG, V769_D770insASV, H773_V774insNPH, or any other exon 20 in-frame insertion or point mutation excluding T790M...
    Trial ID:
    NCI-2017-00831
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

    Excerpt:
    ...- Cohort 6: Patients with EGFR mutation-positive NSCLC who progressed while on treatment with first-line osimertinib...
    Trial ID:
    ZENITH20
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors

    Excerpt:
    ...Patients with EGFR mutation (e.g., G719X, exon 19 deletion, L858R, L861Q, etc) known to be associated with sensitivity to TKIs 2....
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma

    Excerpt:
    ...Documented EGFR mutation (e.g., exon 19 deletion, exon 21 L858R, etc.) with tumor tissue 4....
    Trial ID:
    NCT01819428
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Poziotinib in Japanese Patients With NSCLC

    Excerpt:
    ...- Phase 2: Documented EGFR or HER2 exon 20 insertion mutations (including duplication mutations) in NSCLC patients -...
    Trial ID:
    NCT04402008
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

    Excerpt:
    ...Patient is positive for EGFR or HER2 exon 20 mutations based on tissue testing:...
    Trial ID:
    NCT04044170
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2020
    Title:

    P76.86 - Poziotinib for EGFR and HER2 Exon 20 Insertion Mutation in Advanced NSCLC: Results from the Expanded Access Program.

    Published date:
    01/12/2021
    Excerpt:
    Poziotinib demonstrated clinical activity in mNSCLC patients with EGFR/HER2-exon 20-i-mut…